FGFR3 mutation

Our results indicate that early-onset bladder cancer is a distinct patient population that has disease driven by specific somatic mutations, some of which represent therapeutic targets. This suggests potential benefits of genomic tumor profiling in guiding personalized treatment.

Pan-cancer targeted sequencing provided a comprehensive genomic landscape of UBC, capturing canonical drivers and additional alterations that may be overlooked by bladder-restricted assays. The identification of TP53 and STAG2 as prognostic markers highlights the potential value of broader genomic profiling for biologically informed risk stratification in urothelial bladder cancer.

The analysis reveals a clear trajectory toward more rigorous scientific inquiry in UTUC investigations, with particular emphasis on developing standardized protocols for tumor localization, surgical approaches, and novel treatment modalities. This evolving paradigm reflects the discipline's dedication to advancing therapeutic precision while minimizing risks, suggesting significant potential for subsequent research to refine clinical decision-making and improve prognostic results.

PAK1/2/3 break-apart fluorescence in situ hybridization (FISH) showed no split signals in any case; PAK3 FISH also failed in the same two older specimens. Thus, IFK may represent a distinct clinicopathologic variant of seborrheic keratosis under our proposed diagnostic criteria.

Notably, the score exhibited distinct predictive value across different immune phenotypes, enabling more precise stratification of potentially responsive populations. The SWI_SNF_Score enables quantitative evaluation of molecular and immune heterogeneity in bladder cancer and provides a clinically relevant framework for prognostic stratification and immunotherapy response prediction.

In particular, the dynamic interplay between tumor cell metabolic reprogramming and the immune suppressive tumor microenvironment, collectively termed the "metabolic-immune axis", constitutes a major challenge underlying drug resistance. This review summarizes how this axis, through mechanisms such as enhanced glycolysis and abnormal amino acid/lipid metabolism, influences bladder cancer progression and treatment responsiveness, thereby establishing a theoretical framework for future research directions.

P1/2, N=48, Recruiting, Tyra Biosciences Inc.

Our findings underscore the clinical significance of TROP2 expression in UTUC and suggest that IHC-based evaluation may contribute to prognostic risk stratification.

P=N/A, N=4, Completed, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2027 --> Feb 2026 | Trial primary completion date: Jan 2027 --> Feb 2026 | Active, not recruiting --> Completed

Structural characterization using MALDI-TOF-MS and X-ray crystallography confirmed covalent binding of 10s to FGFR3. Compound 10s also showed significant antitumor efficacy in the RT112/84 bladder cancer xenograft model, offering a promising compound to address both selectivity and resistance in FGFR3-targeted therapy.

P=N/A, N=4, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027

In order to be able to use these therapeutic innovations in a targeted and precise manner in the future, biomarker-based stratification of urothelial carcinomas is likely to play a greater role. Current developments thus open up considerable potential for true precision oncology.